Back to Freepaper Session

Clinical investigation into the safety and efficacy of a presbyopic excimer treatment in post-LASIK Eyes: 6 months follow-up

Session Details

Session Title: Presbyopia Correction

Session Date/Time: Monday 07/10/2013 | 16:30-18:15

Paper Time: 16:42

Venue: Emerald (First Floor)

First Author: : R.Ang PHILIPPINES

Co Author(s): :                  

Abstract Details

Purpose:

To determine the safety and efficacy of an excimer LASIK treatment for presbyopia in patients who have previously undergone LASIK surgery

Setting:

Department of Cornea and Refractive Surgery, Asian Eye Institute, Philippines

Methods:

In this single centre, single surgeon, prospective study, a monolateral Supracor LASIK treatment (Bausch + Lomb Technolas) was performed in 30 post-LASIK presbyopic patients with the Technolas 217P excimer laser. Measured outcomes include visual acuity, safety, refraction and a subjective patient questionnaire over a 6 month follow-up period. Target refraction was -0.5D.

Results:

The mean patient age was 50.8 years. Preoperative mean spherical equivalent (SE) was 0.11D and mean cylinder was 0.5D. At 6 months post-operative (16 eyes), mean SE was -0.32D and mean cylinder was 0.55D. Monocular uncorrected near visual acuity (UNVA) improved from 22% at 0.8 pre-operatively to 69% at 1.0 or better 6 months post-operatively. 81% patients have binocular UNVA of 1.0 or better post-operatively. Uncorrected intermediate visual acuity (UIVA) improved from 31.6% at 1.0 or better pre-operatively to 85.7% at 1.0 better at 6 months post-op. Monocular uncorrected distance visual acuity (UDVA) remained stable post-operatively, with a slight improvement in post-operative binocular UDVA recorded compared with pre-operative. Good patient satisfaction was reported and 94% of patients would recommend the procedure to their friends.

Conclusions:

The initial six month results find the Supracor Lasik procedure is a safe and effective treatment option for post-lasik patients with presbyopia. The procedure improves near and intermediate vision, with minimal impact on distance vision.

Financial Interest:

... receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, ... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, ... research is funded, fully or partially, by a company producing, developing or supplying the product or procedure presented